
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is supported by a stronger post-consumer portfolio that concentrates capital on innovative medicine and medtech, with leadership in immunology, oncology, and neurology, plus category positions in 11 of 12 medtech platforms. The company’s growth case is reinforced by strong prescription trends and launches such as Tremfya, Icotyde, Darzalex, and Spravato, while management expects competitive growth from a pipeline with five $5B-plus and 12 $1B-plus opportunities. Even with MedTech headwinds and a recent ~6% sell-off, the business still appears defensive, cash-generative, and capable of double-digit growth through the end of the decade, with FY26 revenue around $101.0bn and EPS at $11.13.
Bears say
Johnson & Johnson is facing a negative fundamental setup because lower-than-expected organic revenue growth could be driven by weaker pipeline contribution in innovative medicine, faster loss-of-exclusivity erosion, and softer MedTech uptake amid persistent competitive headwinds. In particular, Stelara is already in year two of biosimilar erosion, with full-year erosion guidance of approximately 60% intact and 1H erosion near 57%, while management also flagged lingering electrophysiology and pulsed field ablation pressure that may delay the hoped-for 2H26 MedTech recovery. Additional downside comes from M&A integration risk, litigation and settlement costs, and reduced margin discipline, with 3Q26 EPS estimated at $2.55 versus consensus of $2.81 and OpEx at $10.15bn.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Johnson & Johnson (JNJ) Forecast
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares